LinkedIn Content Strategy for Biotech Messaging Strategists | Netwarm
LinkedIn playbook · Case study
LinkedIn content strategy for biotech messaging strategists: how an Ontario strategist reached 330 biotech founders and CEOs
We read every reaction on 29 posts from an Ontario biotech messaging strategist. 2,694 people, 330 biotech founders and CEOs. Here is what brings buyers, what brings peers, and the 5 posts we'd publish next.
Max Sawyer · Netwarm··10 min read
The creator in this case studyAn Ontario biotech messaging strategist
Followers46,859
Posts~8 a week
SellsLinkedIn personal brands and messaging for biotech CEOs, fractional executive work
These numbers are from 30 October. Your audience has already moved.
New biotech founders and CEOs turn Hot every week and others go quiet. Run your free scan to see today’s version, with the names.
Ideal client: biotech founders and CEOs, many in cell and gene therapy, who want attention, authority and inbound leads from LinkedIn.The challenge: The strategist sells LinkedIn personal brands to biotech CEOs, but posts mostly for the science crowd. The paper breakdowns get the biggest reactions. Do the CEOs read them?
Key takeaways
330 biotech founders and CEOs reacted in October.About 1 reader in 8 (12.2%), and 37 of them came back 3 times or more.
Investors bring the founders, papers bring the crowd.Investor and VC notes brought 26.7% founders and CEOs, science breakdowns 7.8%: 3.4x more.
15 founders and CEOs are Hot right now.They reacted to 5 posts or more. One of them reacted to 18 of the 29.
01
Who actually reads you, and what the LinkedIn algorithm changed
The strategist posts about cell and gene therapy science, conference sessions and the investors who fund the field, about 8 times a week, to 46,859 followers. The offer is something else: LinkedIn personal brands for biotech CEOs.
The LinkedIn algorithm shows a post to the people who reacted to the last ones, then to people like them. Post paper breakdowns and the audience fills with people who love papers. Reach can't tell if the CEOs are in it. Who reacted can. We looked at every person who reacted between 6 and 30 October, and sorted them by role.
29posts in October
2,694people reacted
330biotech founders & CEOs
37came back 3+ times
Audience by roleThe 2,694 people who reacted, by roleFree
Most readers sit outside these groups: people across the field who push reach on the big science posts, and rarely hire a messaging strategist.
The buyers are there: 330 founders and CEOs, plus 267 people in business development and investing, the people founders pitch to. 18.5% of everyone who reacted is a founder, owner or C-level.
SeniorityAll people who reactedFree
Founder, owner, C-level18.5%
Director, VP10.2%
Manager7.6%
Independent4.1%
Other59.5%
IndustriesBiotech founders and CEOs onlyNetwarm
Cell and gene therapy26.4%
Hidden in preview00%
Hidden in preview00%
Hidden in preview00%
See all industries and company sizes in your free scan.
Core audience37 biotech founders and CEOs engaged 3+ times · 15 engaged 5+ timesNetwarm
37 biotech founders and CEOs keep coming back. One of them reacted to 18 of the 29 posts.See your regulars
Engager company sizeEveryone who reacted, by company sizeNetwarm
Hidden in preview00%
Hidden in preview00%
Hidden in preview00%
Hidden in preview00%
Hidden in preview00%
See which company sizes your biotech founders and CEOs work at.See company sizes
02
What to post on LinkedIn to reach biotech founders and CEOs
Most science creators judge a post by its reactions. A strategist who sells to CEOs should judge it by who reacted.
We tagged each of the 29 posts by topic, then measured the share of biotech founders and CEOs among the people who reacted.
Your topicsWhat your 29 posts were aboutFree
29posts
Conference coverage12
Science breakdowns7
Investor & VC notes4
Company & deal news4
Memes2
Topics that attract biotech founders and CEOsShare of each topic’s reactions from biotech founders and CEOsNetwarm
Investor & VC notes26.7%
Conference coverage17.8%
Company & deal news12.9%
Memes9.8%
Science breakdowns7.8%
One topic brings 3.4x more founders and CEOs than another. See which.See which topics
Investor and VC notes bring 3.4x more biotech founders and CEOs per reaction than science breakdowns: 26.7% against 7.8%.
Posts that brought the most biotech founders and CEOsShare of biotech founders and CEOs in each post’s reactions1 of 5 open
#1Where biotech fits in an endowment's LP strategy28.2%
#2A VC and an LP's blueprint for biotech investment26.5%
#3The CGT investment landscape after Meeting on the Mesa23.1%
#4Change is coming to CBER22.8%
#5Arizona Bioscience Week coverage starts22.5%
For comparison, science breakdowns averaged 7.8% founders and CEOs, even though they drew the most reactions: the two biggest (615 and 535 reactions) brought 4.3% and 4.7%.
6 rules for LinkedIn engagement from biotech founders and CEOs
These rules come from what worked on the strategist's own profile, and from the best-performing posts by biotech investors, founders and strategists on LinkedIn over the last 6 months.
1
Write for the people who sign the cheques. Founders read what investors think. A note on how an LP or a VC sees biotech is the closest post to a CEO's real worry: the next raise.On this profile: investor and VC notes brought 26.7% founders and CEOs, science breakdowns 7.8%.
Turn every session into a founder's to-do list. Conference notes work best when each point is something a founder can do on Monday: talk to the people who sold, build a small board, get to proof fast.On this profile: the VC and LP session notes brought 26.5% founders and CEOs, against 17.8% for conference coverage overall.
Compare the bets, don't summarise the paper. A paper breakdown speaks to scientists. A comparison of the choices a company has to make (autologous, allogeneic, in vivo) speaks to the person making them.On this profile: the three-way CAR-T comparison brought 16.8% founders and CEOs, twice the 7.8% average for science breakdowns.
Open with the claim a founder would argue with. “The science didn't get harder, the economics broke.” A reversal in the first line makes a CEO stop and read the rest to disagree.
Put the whole landscape on one page. CEOs save the post that maps their field: who is in it, who bought whom, where the money went. One page beats ten updates.Across the niche: a one-page in vivo CAR landscape drew 1,151 reactions.
Post about what you sell, once a week. The strategist sells founder storytelling, and none of the 29 posts were about it. One founder-messaging post a week shows CEOs what they would be buying.Across the niche: a VC's post on why founders tell their story badly drew 1,030 reactions and 212 comments.
When biotech founders read: the best time to post on LinkedIn for biotech messaging strategists
We compared the share of biotech founders and CEOs by the day each post was published (Toronto time). Days with fewer than 3 posts are left out.
Share of biotech founders and CEOs by posting dayAmong the people who reacted to each postFree
11.8%
Tue
13.8%
Wed
22.0%
Thu
15.2%
Fri
Thursday led with 22% founders and CEOs, against 11.8% on Tuesdays. Part of that is the topic: the two best investor notes went out on a Thursday and a Friday. Give the investor and founder posts the Thursday and Friday slots, and keep Tuesday for the science that brings reach.
By hour, the late-morning posts (10:00, 5 posts) averaged 19.3% founders and CEOs, against 12.6% for the 10 posts at 8:00. Too few posts to be sure, but worth testing.
05
5 posts ready to publish to target biotech founders and CEOs
Each post follows the rules above, in the strategist's voice. Swap in your own details before posting: the real story is what makes it land.
1Ready to postInvestor note
The 3 things investors read firstRules 1 and 2: what investors want, written as a founder's to-do list. Built like the VC and LP session notes.
Hook
A VC told a room of biotech founders what captures attention in a deck. It was 3 things.None of them were the science.1/ Potential return vs. investment
Not the mechanism. The math. What does a win look like, and what does it cost to get there?2/ What you can do that nobody else can
One sentence. If it needs a slide of caveats, it isn't one sentence yet.3/ A need people were not aware of
The hardest of the three. You have to show investors the problem before you show them your answer.Here's what struck me.These are messaging problems, not science problems.I see it with founders all the time. World-class data. A deck that opens on the mechanism of action. And an investor still waiting to hear why it matters.The science earns the second meeting.
The story earns the first one.Founders: which of the 3 is hardest to write for your company?Drop it in the comments.P.S. I turned these 3 questions into a one-page check for your deck and your LinkedIn profile. Comment "STORY" and I'll send it over.
Visual · Single imageThe 3 questions on one slide, in your brand colours. No stock photo.Check before postingHave the one-page check ready before you post the P.S. Keep the founder examples general, or use one you can vouch for.
Three CAR-T bets, three investor questionsRule 3: compare the bets a company makes. Built like the autologous vs. allogeneic vs. in vivo breakdown.
Hook
Autologous vs. Allogeneic vs. In vivo CAR-T: each one gets a different first question from investors.Let's break it down:Autologous
The question: "How do you get cost and logistics down?"
The track record is there. The burden is one batch per patient.
Your answer has to be about manufacturing: automation, standard unit operations, shorter production time.Allogeneic
The question: "How long do the cells last?"
Banked doses remove the wait. Rejection can limit persistence, and no allogeneic CAR-T is FDA approved yet.
Your answer has to be persistence data, not platform slides.In vivo
The question: "Can you get it to the right cells, safely?"
No collection, no external engineering. Delivery is the whole game.
Your answer has to be selectivity and safety, ideally head-to-head against what already works.Same field. Three different stories.The founders who raise fastest answer the question their modality gets before anyone asks it.Building in one of the three? Which question do you get most?Drop it in the comments.
Visual · Carousel4 slides: one per approach with its question in large type, then the closing line.Check before postingSwap in the investor questions you actually hear. Check the approval status is still current on the day you post.
Your science is not your storyRule 6: one post a week about what the strategist sells. Modelled on Harry Stebbings' founder storytelling post.
Hook
Most biotech CEOs post their science on LinkedIn.
Then wonder why investors don't call.Here's the thing: your science is the proof. It is not the story.I spoke with a CEO running a gene therapy company recently. Brilliant data. Every post was a figure from a paper.I asked one question: "Why did you start this company?"She told me about the first patient family she met. Ten minutes later we had a year of posts.Here's the order that works:1/ Start with the moment, not the mechanism
The patient, the failed experiment, the meeting that went sideways.2/ Then give the lesson
3 numbered takeaways. That's where your expertise lives.3/ Then show the data
Now it means something.Story first. Science second.Founders: what's the moment that made you start your company?Drop it in the comments.
Visual · Text onlyNo image. The question in the comments does the work.Check before postingUse a real conversation (with the client's OK and no names) or your own founding story.
October in CGT investing, on one pageRule 5: the whole landscape on one page. Modelled on Maryam Daneshpour's in vivo CAR landscape.
Hook
October in cell and gene therapy investing, on one page.I spent a week at Meeting on the Mesa and Arizona Bioscience Week asking investors and leaders where the money is going.Here's the whole picture:1/ Fewer investors, better conversations
The total number of investors is down. The quality of conversations is up. Cautious optimism.2/ "Reason to dream again"
Investment is ticking up, more approvals are coming through, and there's progress with leadership at CBER.3/ CBER is getting more flexible
Especially for new modalities. Flexibility brings some uncertainty, but it's a move in the right direction.4/ China is "punch drunk on capital"
A crunch is coming for the companies chasing the exact same targets.5/ LPs are starting to go direct
Endowments will look at a single company on its own merits, if the return potential is demonstrable.6/ Biotech still offers a shot at 10x
That ceiling is why allocators keep paying attention.The bar is higher. The money is still there for the companies that can explain themselves.What did I miss?Drop it in the comments.
Visual · Single imageOne page: the 6 points as a grid, with the speaker's name under each quote.Check before postingCredit each speaker by name, as in the original coverage posts.
Your pipeline slide might be hurting your raiseRule 4: open with a claim founders will argue with. Modelled on David Berry's “the economics broke” post.
Hook
Your pipeline slide might be hurting your raise.That's not my take. It came from a VC and an LP in Arizona.Their advice to founders: be singularly focused on the next catalyst.Multiple parallel priorities are how biotech companies lose the plot. (They used the Caribou Biosciences shutdown as the example.)I think about this every time a founder walks me through their deck.Five programs. Three modalities. A platform slide. And no clear answer to: what happens next, and when?Here's the reframe:
→ One catalyst. What gets proven next?
→ One reason it's you. What can you do that nobody else can?
→ One number. What's it worth if it works?Everything else goes in the appendix.Founders: agree or disagree?Let me know in the comments.
Visual · Text onlyNo image. Let the first line start the argument.Check before postingKeep the founder examples anonymous. Use a deck you've really seen, or keep it general.
Free forever: unlimited scheduling through LinkedIn’s official API, with images, video and PDF carousels.
06
LinkedIn lead generation: lead magnets that work to target biotech founders and CEOs
Reactions show interest. A download shows intent. The fastest way to find out which founders and CEOs are serious is to give them something useful and see who takes it.
In biotech, these formats get the most requests:
Format 1The one-page mapA system founders struggle with, drawn on one page and sent as a PDF.
Format 2The toolSomething founders use on their own work, given away for a comment.
Format 3The investor's checklistWhat investors check, given to founders before they pitch.
Format 4The dataA map or list of companies in the field, free to explore.
Our pick for you: “The 3-question investor story check”Format 3, built from the VC and LP session the strategist already covered: the three things investors read first (return vs. investment, what only you can do, the need nobody saw), as a one-page check for a deck and a LinkedIn profile. Offer it in the P.S. of post 1.With a Reveal link, every person who downloads it is shown by name, with their role and how warm they are. Your first Reveal link is free.Create your free Reveal link
07
From reactions to clients
Content brings biotech founders and CEOs to the profile. It doesn't say when to reach out. Most never comment, so they stay invisible, and a CEO reading every investor note in October may have hired someone else by January. 14 founders and CEOs who reacted 3 or more times in early October haven't reacted in the last 3 weeks.
On LinkedIn, the right moment to start a conversation is when someone keeps coming back. We call that Hot: 5 or more points over 90 days, where a reaction counts 1, a repost 2, a download or a reply 4.
Hot right now15 biotech founders and CEOs · not contacted yetNetwarm
15 biotech founders and CEOs are Hot. See who to message first.See who’s Hot
First messageAn opener for each Hot person, based on the posts they readNetwarm
Hi Jordan, you've been reading the investor notes from Arizona. Is a raise on the cards this year?Hi Sam, I saw you reacted to the VC and LP session notes. Did the board advice ring true for you?
A first line for each of them, ready to send.See the openers
Netwarm sends nothing for you. It tells you who and when, and you write the message. It also works inside Claude and ChatGPT: ask “Who's Hot today?” and get the list.
08
FAQ
What investors think, written for founders. Investor and VC notes brought 26.7% founders and CEOs here, conference coverage 17.8%, science breakdowns 7.8%. Keep the science for reach, and add one post a week about the founder messaging you sell.
For this strategist, Thursday (22% founders and CEOs) and Friday (15.2%), against 11.8% on Tuesday. The best investor notes went out on those days, so the topic explains part of the gap.
They bring reach: the two biggest posts of the month were science breakdowns. But they brought under 5% founders and CEOs. Use them to grow, and the investor and founder posts to sell.
Look at who reacts, not how many. Group reactions by role, measure the share of your ideal clients per post, and follow the people who keep coming back. A free Netwarm scan does this for you.
Yes. Netwarm only reads public reactions to your own posts. It never logs in as you, never asks for your password, and never messages anyone for you.
How we made this playbook
We read the public reactions on 29 posts published between 6 and 30 October 2026 (one deleted duplicate left out), and sorted the 2,694 people by role. The biggest posts were read up to their first 300 reactions, and comments were not counted, so figures are a floor.
Niche rules come from top posts by biotech investors, founders and strategists over the last 6 months. Role groups are approximate; a Netwarm scan matches people to your own ideal client.